QAX576

Idiopathic Pulmonary Fibrosis

Clinical trials

Developer

Novartis Pharmaceuticals

Overview

QAX576 is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 3 tracked IPF clinical trials.

QAX576 clinical trials

NCT00532233 (Phase 2)NCT01266135 (Phase 2)NCT00581997 (Phase 2)

Explore related

All trials Research

Medical disclaimer. This page summarizes research about QAX576 for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.